Portzamparc Groupe BNP Paribas is proud to have supported Valbiotis (www.valbiotis.com/fr-fr/), a French laboratory specialized in the design and distribution of dietary supplements, in its c.€7 million capital increase aiming to support the commercial expansion of its product offering.
Portzamparc Groupe BNP Paribas acted as Joint Global Coordinator of the transaction.
👉 Details of the transaction:
Capital increase of c.€7m to finance the commercial expansion of Valbiotis’ dietary supplements offering.
Strong interest from existing shareholders, with over €3.0m demand within the preferential subscription rights period.
Sébastien Peltier, Co-founder and Chairman of the Management Board, renewed his commitment by subscribing to the transaction.
